Pierre Fabre
http://www.pierre-fabre.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pierre Fabre
Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
Pfizer Builds On AI/ML Pact With CytoReason With New Five-Year Deal
Deal Snapshot: The companies first partnered in January 2019, with a focus on more than 20 diseases. The renewed deal will support development of additional disease models using artificial intelligence and machine learning.
Academic Study Boosts Belief In TIL Therapies, Including Iovance’s Lifileucel
A new academic study presented at ESMO has provided the first Phase III data for tumor-infiltrating lymphocytes as a potential new therapeutic class, while industry leader Iovance looks set to have early-stage data for its TIL accepted by the US FDA.
Cardio Catch-Up: Arga, HeartPoint Plan First-In-Human Trials Of Novel Devices; Medtronic And Edwards Announce Product Launches, And More
The second half of summer is usually a slow time for news about cardiac technology innovations because there are not many major conferences. But there was still plenty of innovation news coming from both small and big cardiovascular device companies in July and August.
Company Information
- Industry
- Distributors
- Pharmaceuticals
-
Services
- Pharmacy Services, PBMs
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Pierre Fabre Medicament S.A.